{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:27:17Z","timestamp":1740108437048,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006676","name":"Lilly Deutschland","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00296-019-04244-5","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T10:30:28Z","timestamp":1548412228000},"page":"605-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-2825","authenticated-orcid":false,"given":"Phuong Anh","family":"Pham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-2062","authenticated-orcid":false,"given":"Corinna","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-1094","authenticated-orcid":false,"given":"Lisa","family":"Eisert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-2203","authenticated-orcid":false,"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-1392","authenticated-orcid":false,"given":"Ricardo Niklas","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"4244_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12659\/PJR.883763","volume":"78","author":"AJ Sankowski","year":"2013","unstructured":"Sankowski AJ, \u0141ebkowska UM, \u0106wik\u0142a J, Walecka I, Walecki J (2013) Psoriatic arthritis. Pol J Radiol 78:7\u201317. \n                    https:\/\/doi.org\/10.12659\/PJR.883763","journal-title":"Pol J Radiol"},{"key":"4244_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45:151\u2013158. \n                    https:\/\/doi.org\/10.1002\/1529-0131(200104)45:2%3C151::aid-anr168%3E3.0.co;2-t","journal-title":"Arthritis Rheum"},{"key":"4244_CR3","first-page":"809","volume":"17","author":"DD Gladman","year":"1990","unstructured":"Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17:809\u2013812","journal-title":"J Rheumatol"},{"key":"4244_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11926-013-0316-4","volume":"15","author":"L Eder","year":"2013","unstructured":"Eder L, Gladman DD (2013) Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep 15:316. \n                    https:\/\/doi.org\/10.1007\/s11926-013-0316-4","journal-title":"Curr Rheumatol Rep"},{"key":"4244_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351\u2013360. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"4244_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41:545\u2013568","journal-title":"Rheum Dis Clin N Am"},{"key":"4244_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","volume":"73","author":"R Goulabchand","year":"2014","unstructured":"Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B (2014) Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 73:414\u2013419. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-202641","journal-title":"Ann Rheum Dis"},{"key":"4244_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337","author":"L Gossec","year":"2015","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Ca\u00f1ete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"key":"4244_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73:3\u20135. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204317","journal-title":"Ann Rheum Dis"},{"key":"4244_CR10","unstructured":"Sabat\u00e9 E (2003) Adherence to long-term therapies: evidence for action. World HealthOrganization. \n                    https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/\n                    \n                  . Accessed 12 Jan 2017"},{"key":"4244_CR11","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. \n                    http:\/\/handbook.cochrane.org\n                    \n                  . Accessed 12 Jan 2017"},{"key":"4244_CR12","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. \n                    https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"4244_CR13","first-page":"1167","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34:1167\u2013117014","journal-title":"J Rheumatol"},{"key":"4244_CR14","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/jid.2013.78","volume":"133","author":"A Nast","year":"2013","unstructured":"Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J (2013) Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Investig Dermatol 133:1963\u20131970. \n                    https:\/\/doi.org\/10.1038\/jid.2013.78","journal-title":"J Investig Dermatol"},{"key":"4244_CR15","unstructured":"Dean AGSK, Soe MM (2013) OpenEpi: open source epidemiologic statistics for public health, version. \n                    https:\/\/openepi.com\n                    \n                  . Accessed 06 Jun 2018"},{"key":"4244_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/14651858.CD201601","volume":"10","author":"JPT Higgins","year":"2016","unstructured":"Higgins JPT, Sterne JAC, Savovi\u0107 J, Page MJ, Hr\u00f3bjartsson A, Boutron I, Reeves B, Eldridge S (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10:29\u201331. \n                    https:\/\/doi.org\/10.1002\/14651858.CD201601","journal-title":"Cochrane Database Syst Rev"},{"key":"4244_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.ch9","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2008) Analysing data and undertaking meta-analyses. Cochrane Handb Syst Rev Interv. \n                    https:\/\/doi.org\/10.1002\/9780470712184.ch9","journal-title":"Cochrane Handb Syst Rev Interv"},{"key":"4244_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","volume":"31","author":"S Greenland","year":"2016","unstructured":"Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG (2016) Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 31:337\u2013350. \n                    https:\/\/doi.org\/10.1007\/s10654-016-0149-3","journal-title":"Eur J Epidemiol"},{"key":"4244_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, Investigators R (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541\u2013548","journal-title":"Ann Rheum Dis"},{"key":"4244_CR20","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1002\/art.39977","volume":"68","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Hall S, Gerald OF, Heijde D, Merola JF, Avila-Zapata F, Cieslak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik K (2017) Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDS: a randomized, placebo-controlled, phase 3 trial. Arthritis Rheumatol 68:3975\u20133978. \n                    https:\/\/doi.org\/10.1002\/art.39977","journal-title":"Arthritis Rheumatol"},{"key":"4244_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2016","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Cuchacovich RS, Shuler CL, Lin CY et al (2016) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebocontrolled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79\u201387. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709","journal-title":"Ann Rheum Dis"},{"key":"4244_CR22","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"G Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156\u20133167","journal-title":"Arthritis Rheum"},{"key":"4244_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48\u201355","journal-title":"Ann Rheum Dis"},{"key":"4244_CR24","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gomez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A (2012) Golimumab in psoriatic arthritis: 1-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64:2504\u20132517","journal-title":"Arthritis Rheum"},{"key":"4244_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986","journal-title":"Arthritis Rheum"},{"key":"4244_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, Future Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329\u20131339","journal-title":"N Engl J Med"},{"key":"4244_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, Heijde D, Landew\u00e9 R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137\u20131146. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)61134-5","journal-title":"Lancet"},{"key":"4244_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L (2018) Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 20:47. \n                    https:\/\/doi.org\/10.1186\/s13075-018-1551-x","journal-title":"Arthritis Res Ther"},{"key":"4244_CR29","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1002\/art.39977","volume":"68","author":"DD Gladman","year":"2017","unstructured":"Gladman DD, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: opal beyond, a randomized, double blind, placebo-controlled, phase 3 trial. Arthritis Rheumatol 68:4371\u20134375. \n                    https:\/\/doi.org\/10.1002\/art.39977","journal-title":"Arthritis Rheumatol"},{"key":"4244_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.13258","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M (2016) Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol 43:869\u2013880","journal-title":"J Dermatol"},{"key":"4244_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, Psummit Study Group (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789","journal-title":"Lancet"},{"key":"4244_CR32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, Psummit Study Group (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990\u2013999","journal-title":"Ann Rheum Dis"},{"key":"4244_CR33","doi-asserted-by":"publisher","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","volume":"1","author":"P Mease","year":"2015","unstructured":"Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczynski P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewe R, de Longueville M, Hoepken B, Peterson L, van der Heijde D (2015) Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 1:e000119. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2015-000119","journal-title":"RMD Open"},{"key":"4244_CR34","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester G-R, Adams D, Kerr L, Lee C, Shuler C, Genovese M (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389:2317\u20132327. \n                    https:\/\/doi.org\/10.1016\/S0140-6736%2817%2931429-0","journal-title":"Lancet"},{"key":"4244_CR35","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150\u20131157. \n                    https:\/\/doi.org\/10.1136\/ard.2004.032268","journal-title":"Ann Rheum Dis"},{"key":"4244_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"4244_CR37","first-page":"1040","volume":"34","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1040\u20131050","journal-title":"J Rheumatol"},{"key":"4244_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633\u2013640. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60140-9","journal-title":"Lancet"},{"key":"4244_CR39","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol 69:2151\u20132161. \n                    https:\/\/doi.org\/10.1002\/art.40226","journal-title":"Arthritis Rheumatol"},{"key":"4244_CR40","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cie\u015blak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537\u20131550. \n                    https:\/\/doi.org\/10.1056\/NEJMoa161597542","journal-title":"N Engl J Med"},{"key":"4244_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349\u2013356","journal-title":"Ann Rheum Dis"},{"key":"4244_CR42","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289. \n                    https:\/\/doi.org\/10.1002\/art.21306","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4244_CR43","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264\u20132272","journal-title":"Arthritis Rheum"},{"key":"4244_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","volume":"59","author":"H Torii","year":"2010","unstructured":"Torii H, Nakagawa H, Japanese Infliximab Study investigators (2010) Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 59:40\u201349. \n                    https:\/\/doi.org\/10.1016\/j.jdermsci.2010.04.014","journal-title":"J Dermatol Sci"},{"key":"4244_CR45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ard.2008.091389","volume":"68","author":"AW Kuijk van","year":"2009","unstructured":"van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman AH, Dijkmans BA, Tak PP (2009) A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 68:1303\u20131309. \n                    https:\/\/doi.org\/10.1136\/ard.2008.09138947","journal-title":"Ann Rheum Dis"},{"key":"4244_CR46","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/art.39977","volume":"68","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Genovese MC, Weinblatt M, Peloso PM, Chen K, Li Y, Mansikka HT, Khatri A, Othman AA, Wishart N, Liu J, Padley RJ (2017) Safety and efficacy of ABT-122, a TNF and IL-17-targeted dual variable domain (DVD)-IgTM, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial. Arthritis Rheumatol 68:1268\u20131270. \n                    https:\/\/doi.org\/10.1002\/art.39977","journal-title":"Arthritis Rheumatol"},{"key":"4244_CR47","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525\u20131536. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"key":"4244_CR48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, G\u00f3mez-Reino JJ, Aelion JA (2018) Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77:690\u2013698. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211568","journal-title":"Ann Rheum Dis"},{"key":"4244_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/OAJCT.S34419","volume":"5","author":"F Song","year":"2013","unstructured":"Song F, Hooper L, Loke Y (2013) Publication bias: what is it? How do we measure it? How do we avoid it? Open Access J Clin Trials 5:71\u201381. \n                    https:\/\/doi.org\/10.2147\/OAJCT.S34419","journal-title":"Open Access J Clin Trials"},{"key":"4244_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242","author":"A-M Orbai","year":"2016","unstructured":"Orbai A-M, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A (2016) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210242","journal-title":"Ann Rheum Dis"},{"key":"4244_CR51","first-page":"247","volume":"17","author":"KA Papp","year":"2017","unstructured":"Papp KA, Lebwohl MG (2017) Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol 17:247\u2013250","journal-title":"J Drugs Dermatol"},{"key":"4244_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","volume":"2","author":"LJ Savage","year":"2015","unstructured":"Savage LJ, Wittmann M, McGonagle D, Helliwell PS (2015) Ustekinumab in the treatment of psoriasis and psoriatic arthritis. Rheumatol Ther 2:1\u201316. \n                    https:\/\/doi.org\/10.1007\/s40744-015-0010-2","journal-title":"Rheumatol Ther"},{"key":"4244_CR53","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O\u2019Keeffe AG, Maddison PJ, Scott DL (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 51:1368\u20131377. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology"},{"key":"4244_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000212","author":"G Jones","year":"2000","unstructured":"Jones G, Crotty M, Brooks P (2000) Interventions for treating psoriatic arthritis. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD000212","journal-title":"Cochrane Database Syst Rev"},{"key":"4244_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, Thompson SG, Spiegelhalter DJ (2008) A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A (Statistics in Society) 172:137\u2013159. \n                    https:\/\/doi.org\/10.1111\/j.1467-985X.2008.00552.x","journal-title":"J R Stat Soc Ser A (Statistics in Society)"},{"issue":"10","key":"4244_CR56","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1185\/03007995.2010.515804","volume":"26","author":"A Kavanaugh","year":"2010","unstructured":"Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB (2010) Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 26(10):2385\u20132392. \n                    https:\/\/doi.org\/10.1185\/03007995.2010.515804","journal-title":"Curr Med Res Opin"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04244-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04244-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04244-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:17:01Z","timestamp":1579893421000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04244-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4244"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04244-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors Phuong Anh Pham (PAP), Dr. Corinna Dressler (CD), Ricardo N. Werner, MD (RNW) declare that they have no conflicts of interest. Author Lisa Eisert, MD (LE) has received seminar participation fees from Pfizer (Enbrel), Leo Pharma (Daivobet, Protopic, Enstilar). Author Prof. Alexander Nast, MD (AN) has received institutional research grants\/participated as an investigator (without personal honoraria) in research projects, advisory activities or trials from the following companies with an interest in psoriatic arthritis: Lilly, Novartis, Dermira. AN has received personal honoraria for lectures\/educational activities from the following companies which\u2014to his knowledge\u2014currently have no interest in psoriatic arthritis: Bayer Healthcare, Pierre Fabre, Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}